Medtronic (NYSE:MDT) Releases FY 2027 Earnings Guidance

Medtronic (NYSE:MDT) updated its FY 2027 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 5.900-6.000 for the period, compared to the consensus estimate of 6.060. The company issued revenue guidance of -.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Barclays increased their price objective on shares of Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 1st. JPMorgan Chase & Co. dropped their price objective on shares of Medtronic from $100.00 to $86.00 and set a “neutral” rating on the stock in a research note on Thursday. Sanford C. Bernstein reiterated an “outperform” rating and set a $97.00 price objective on shares of Medtronic in a research note on Thursday. TD Cowen reiterated a “buy” rating and set a $119.00 price objective on shares of Medtronic in a research note on Thursday. Finally, Weiss Ratings lowered shares of Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, May 21st. Sixteen research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $98.70.

Medtronic Stock Performance

MDT opened at $81.95 on Friday. The business’s 50 day moving average is $81.58 and its 200-day moving average is $92.11. The stock has a market cap of $105.22 billion, a PE ratio of 21.97, a price-to-earnings-growth ratio of 1.89 and a beta of 0.58. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. Medtronic has a twelve month low of $73.31 and a twelve month high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. The company had revenue of $9.81 billion for the quarter, compared to analysts’ expectations of $9.62 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.20%.The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.62 earnings per share. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, analysts predict that Medtronic will post 5.97 earnings per share for the current year.

Medtronic Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.5%. This is a boost from Medtronic’s previous quarterly dividend of $0.71. The ex-dividend date of this dividend is Friday, June 26th. Medtronic’s dividend payout ratio is presently 79.11%.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic beat fiscal Q4 revenue expectations with $9.81 billion in sales and posted EPS of $1.55, while management highlighted the strongest annual revenue growth in a decade. Medtronic PLC (MDT) Q4 2026 Earnings Call Highlights: Record Revenue Growth and Strategic …
• Positive Sentiment: The company raised its quarterly dividend to $0.72 per share, signaling confidence in cash flow and shareholder returns. Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United States
• Positive Sentiment: Analysts pointed to accelerating organic growth and the Hugo robotic surgery rollout as reasons for optimism; BTIG upgraded Medtronic to Buy, and several other firms reiterated bullish or constructive ratings. Wall Street May Be Mispricing Medtronic, Analyst Says
• Neutral Sentiment: Medtronic’s surgical expansion is progressing, with new FDA filings and clearances for Hugo RAS in general and gynecologic procedures, which supports the long-term growth story but is still early-stage. Medtronic Balances Hugo Robotics Expansion With Ongoing Cardiovascular Device Recalls
• Neutral Sentiment: Several Wall Street firms reduced price targets after earnings, reflecting caution around margins and FY2027 guidance, though most still kept neutral-to-positive ratings. How To Earn $500 A Month From Medtronic Stock After Q4 Earnings
• Negative Sentiment: Medtronic’s FY2027 EPS guidance of $5.90 to $6.00 came in below the consensus view, and some analysts cited tariff and cost pressures as headwinds. Medtronic (MDT) Climbs 5.7% on Stellar Q4

Institutional Investors Weigh In On Medtronic

Hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP boosted its holdings in shares of Medtronic by 35.3% in the third quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company’s stock valued at $970,456,000 after acquiring an additional 2,658,981 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of Medtronic by 68.3% in the third quarter. AQR Capital Management LLC now owns 3,329,414 shares of the medical technology company’s stock valued at $314,397,000 after acquiring an additional 1,350,888 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in shares of Medtronic by 19.0% in the third quarter. Lazard Asset Management LLC now owns 6,001,342 shares of the medical technology company’s stock valued at $571,502,000 after acquiring an additional 957,149 shares in the last quarter. Schroder Investment Management Group boosted its holdings in shares of Medtronic by 12.5% in the fourth quarter. Schroder Investment Management Group now owns 8,468,982 shares of the medical technology company’s stock valued at $813,530,000 after acquiring an additional 939,133 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in shares of Medtronic by 62.6% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,430,723 shares of the medical technology company’s stock valued at $231,502,000 after acquiring an additional 935,941 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).